Jonathan Garza, MD
Neurology · Houston, TXNPI 1912080250
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,120 of the $2,625 with a category attached, or 80.8%. It is spread thinly across 14 manufacturers, the largest accounting for just 17.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $893 and has fallen 79.2% since, to $185 in 2025. That places this record below the midpoint for neurology clinicians in TX, where the typical reported total is $2,170.
Across 37 payments — averaging $70.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$460
- AbbVie$419
- Novartis$334
- Biogen$311
- SK Life Science, Inc.$201
- Argenx US, Inc.$160
- plus $740 from 8 others
Across 6 payments — averaging $54,077 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$295K
- Novartis$29K
What the payments were for
- Consulting fees$1506%
- Speaking & faculty fees$25210%
- Food & beverage$2,12081%
- Education$1034%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 3 | $460 |
| AbbVie(2 entities) | 8 | $419 |
| Novartis | 3 | $334 |
| Biogen | 5 | $311 |
| SK Life Science, Inc. | 2 | $201 |
| Argenx US, Inc. | 3 | $160 |
| Acadia Pharmaceuticals Inc | 2 | $151 |
| Abbott | 4 | $128 |
| Boston Scientific | 1 | $126 |
| Acorda Therapeutics, Inc | 2 | $107 |
| Amgen | 1 | $102 |
| Teva Pharmaceuticals USA, Inc. | 1 | $87 |
| Sunovion Pharmaceuticals Inc. | 1 | $21 |
| GE HealthCare | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,625 in reported general payments places this provider in the 50th percentile of 1,246 neurology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 12 | $100,632 |
| NuplazidPimavanserin Tartrate | 18 | $92,094 |
| XcopriCenobamate | 22 | $42,671 |
| AptiomEslicarbazepine Acetate | 12 | $29,277 |
| Memantine Hcl | 217 | $22,206 |
| Trokendi XrTopiramate | 16 | $21,068 |
| Duloxetine Hcl | 358 | $18,504 |
| Aimovig AutoinjectorErenumab-Aooe | 16 | $15,701 |
| Donepezil Hcl | 603 | $14,131 |
| Dalfampridine ErDalfampridine | 19 | $11,409 |
| Galantamine ErGalantamine Hbr | 68 | $10,563 |
| Gabapentin | 539 | $8,583 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 81 | $8,523 |
| Levetiracetam | 195 | $8,240 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 187 | $8,092 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $151 | $92,09418 claims |
| SK Life Science, Inc.Xcopri | $201 | $42,67122 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $21 | $29,27712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,246 neurology providers in Texas.
Other neurology in Houston
- William OndoHouston$1.4M
- Pankaj SatijaHouston$1.1M
- Annette HowardHouston$826K
- Randolph EvansHouston$493K
- Leorah FreemanHouston$401K
- Mazen DimachkieHouston$388K
- Zsila SadighiHouston$361K
- Joseph JankovicHouston$323K
- Raja MehannaHouston$300K
- Eddie PattonHouston$299K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.